Skip to main content
SpringerLink
Log in

Missing Data for an Evidence-Based Approach to the Treatment of a Patent Ductus Arteriosus A Small Selection of What We Do not Know Yet

  • Chapter
Controversies around treatment of the open duct

  • 282 Accesses

Abstract

More than 50 years after the description of persistent patency of the arterial duct in preterm infants [1], there is still or rather again controversy on the appropriate management of the patent duct despite publication of more than 75 randomized controlled trials that enrolled more than 6617 patients [2].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 16.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Burnard ED (1959) The cardiac murmur in relation to symptoms in the newborn. Br Med J 1: 134–138

    Article  PubMed  CAS  Google Scholar 

  2. Benitz WE (2010) Treatment of persistent patent ductus arteriosus in preterm infants: time to accept the null hypothesis? J Perinatol 30: 241–252

    Article  PubMed  CAS  Google Scholar 

  3. Marshall DD, Kotelchuck M, Young TE et al. (1999) Risk factors for chronic lung disease in the surfactant era: a North Carolina population-based study of very low birth weight infants. North Carolina Neonatologists Association. Pediatrics 104: 1345–1350

    Article  PubMed  CAS  Google Scholar 

  4. Redline RW, Wilson-Costello D, Hack M (2002) Placental and other perinatal risk factors for chronic lung disease in very low birth weight infants. Pediatr Res 52: 713–719

    PubMed  Google Scholar 

  5. Oh W, Poindexter BB, Perritt R et al. (2005) Association between fluid intake and weight loss during the first ten days of life and risk of bronchopulmonary dysplasia in extremely low birth weight infants. J Pediatr 147: 786–790

    Article  PubMed  Google Scholar 

  6. Kluckow M, Evans N (2000) Ductal shunting, high pulmonary blood flow, and pulmonary hemorrhage. J Pediatr 137: 68–72

    Article  PubMed  CAS  Google Scholar 

  7. Dollberg S, Lusky A, Reichman B (2005) Patent ductus arteriosus, indomethacin and necrotizing enterocolitis in very low birth weight infants: a population-based study. J Pediatr Gastroenterol Nutr 40: 184–188

    Article  PubMed  CAS  Google Scholar 

  8. Dykes FD, Lazzara A, Ahmann P et al. (1980) Intraventricular hemorrhage: a prospective evaluation of etiopathogenesis. Pediatrics 66: 42–49

    PubMed  CAS  Google Scholar 

  9. Evans N, Kluckow M (1996) Early ductal shunting and intraventricular haemorrhage in ventilated preterm infants. Arch Dis Child Fetal Neonatal Ed 75: F183–186

    Article  PubMed  CAS  Google Scholar 

  10. Shortland DB, Gibson NA, Levene MI et al. (1990) Patent ductus arteriosus and cerebral circulation in preterm infants. Dev Med Child Neurol 32: 386–393

    Article  PubMed  CAS  Google Scholar 

  11. Drougia A, Giapros V, Krallis N et al. (2007) Incidence and risk factors for cerebral palsy in infants with perinatal problems: a 15-year review. Early Hum Dev 83: 541–547

    Article  PubMed  CAS  Google Scholar 

  12. Brooks JM, Travadi JN, Patole SK, Doherty DA, Simmer K (2005) Is surgical ligation of patent ductus arteriosus necessary? The Western Australian experience of conservative management. Arch Dis Child Fetal Neonatal Ed 90: F235–239

    Article  PubMed  CAS  Google Scholar 

  13. Noori S, McCoy M, Friedlich P et al. (2009) Failure of ductus arteriosus closure is associated with increased mortality in preterm infants. Pediatrics 123: e138–144

    Article  PubMed  Google Scholar 

  14. Friedman WF, Hirschklau MJ, Printz MP, Pitlick PT, Kirkpatrick SE (1976) Pharmacologic closure of patent ductus arteriosus in the premature infant. N Engl J Med 295: 526–529

    Article  PubMed  CAS  Google Scholar 

  15. Heymann MA, Rudolph AM, Silverman NH (1976) Closure of the ductus arteriosus in premature infants by inhibition of prostaglandin synthesis. N Engl J Med 295: 530–533

    Article  PubMed  CAS  Google Scholar 

  16. Patel J, Marks KA, Roberts I, Azzopardi D, Edwards AD (1995) Ibuprofen treatment of patent ductus arteriosus. Lancet 346: 255

    Article  PubMed  CAS  Google Scholar 

  17. Varvarigou A, Bardin CL, Beharry K et al. (1996) Early ibuprofen administration to prevent patent ductus arteriosus in premature newborn infants. JAMA 275: 539–544

    Article  PubMed  CAS  Google Scholar 

  18. Kitterman JA, Edmunds LH Jr, Gregory GA et al. (1972) Patent ducts arteriosus in premature infants. Incidence, relation to pulmonary disease and management. N Engl J Med 287: 473–477

    Article  PubMed  CAS  Google Scholar 

  19. Van Overmeire B, Allegaert K, Casaer A et al. (2004) Prophylactic ibuprofen in premature infants: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 364: 1945–1949

    Article  PubMed  Google Scholar 

  20. Clyman R, Cassady G, Kirklin JK, Collins M, Philips JB 3rd (2009) The role of patent ductus arteriosus ligation in bronchopulmonary dysplasia: reexamining a randomized controlled trial. J Pediatr 154: 873–876

    Article  PubMed  Google Scholar 

  21. Schmidt B, Davis P, Moddemann D et al. (2001) Long-term effects of indomethacin prophylaxis in extremely-low-birth-weight infants. N Engl J Med 344: 1966–1972

    Article  PubMed  CAS  Google Scholar 

  22. Fowlie PW, Davis PG, McGuire W (2010) Prophylactic intravenous indomethacin for preventing mortality and morbidity in preterm infants. Cochrane Database Syst Rev CD000174

    Google Scholar 

  23. Clyman RI, Saha S, Jobe A, Oh W (2007) Indomethacin prophylaxis for preterm infants: the impact of 2 multicentered randomized controlled trials on clinical practice. J Pediatr 150: 46–50 e2

    Article  PubMed  CAS  Google Scholar 

  24. Schmidt B, Roberts RS, Fanaroff A et al. (2006) Indomethacin prophylaxis, patent ductus arteriosus, and the risk of bronchopulmonary dysplasia: further analyses from the Trial of Indomethacin Prophylaxis in Preterms (TIPP). J Pediatr 148: 730–734

    Article  PubMed  CAS  Google Scholar 

  25. Hamrick SE, Hansmann G (2010) Patent ductus arteriosus of the preterm infant. Pediatrics 125: 1020–1030

    Article  PubMed  Google Scholar 

  26. Vohr BR, Allan WC, Westerveld M et al. (2003) School-age outcomes of very low birth weight infants in the indomethacin intraventricular hemorrhage prevention trial. Pediatrics 111: e340–346

    Article  PubMed  Google Scholar 

  27. Ment LR, Vohr BR, Makuch RW et al. (2004) Prevention of intraventricular hemorrhage by indomethacin in male preterm infants. J Pediatr 145: 832–834

    Article  PubMed  CAS  Google Scholar 

  28. Su BH, Peng CT, Tsai CH (1999) Echocardiographic flow pattern of patent ductus arteriosus: a guide to indomethacin treatment in premature infants. Arch Dis Child Fetal Neonatal Ed 81: F197–200

    Article  PubMed  CAS  Google Scholar 

  29. Carmo KB, Evans N, Paradisis M (2009) Duration of indomethacin treatment of the preterm patent ductus arteriosus as directed by echocardiography. J Pediatr 155: 819–822 e1

    Article  PubMed  Google Scholar 

  30. Clyman RI (1996) Recommendations for the postnatal use of indomethacin: an analysis of four separate treatment strategies. J Pediatr 128: 601–607

    Article  PubMed  CAS  Google Scholar 

  31. Knight DB (2001) The treatment of patent ductus arteriosus in preterm infants. A review and overview of randomized trials. Semin Neonatol 6: 63–73

    Article  PubMed  CAS  Google Scholar 

  32. Cooke L, Steer P, Woodgate P (2003) Indomethacin for asymptomatic patent ductus arteriosus in preterm infants. Cochrane Database Syst Rev CD003745

    Google Scholar 

  33. McNamara PJ, Sehgal A (2007) Towards rational management of the patent ductus arteriosus: the need for disease staging. Arch Dis Child Fetal Neonatal Ed 92: F424–427

    Article  PubMed  Google Scholar 

  34. Laughon MM, Simmons MA, Bose CL (2004) Patency of the ductus arteriosus in the premature infant: is it pathologic? Should it be treated? Curr Opin Pediatr 16: 146–151

    Article  PubMed  Google Scholar 

  35. Ohlsson A, Walia R, Shah SS (2010) Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants. Cochrane Database Syst Rev:CD003481

    Google Scholar 

  36. Sperandio M, Beedgen B, Feneberg R et al. (2005) Effectiveness and side effects of an escalating, stepwise approach to indomethacin treatment for symptomatic patent ductus arteriosus in premature infants below 33 weeks of gestation. Pediatrics 116: 1361–1366

    Article  PubMed  Google Scholar 

  37. Gork AS, Ehrenkranz RA, Bracken MB (2008) Continuous infusion versus intermittent bolus doses of indomethacin for patent ductus arteriosus closure in symptomatic preterm infants. Cochrane Database Syst Rev: CD006071

    Google Scholar 

  38. Herrera C, Holberton J, Davis P (2007) Prolonged versus short course of indomethacin for the treatment of patent ductus arteriosus in preterm infants. Cochrane Database Syst Rev: CD003480

    Google Scholar 

  39. Aly H, Lotfy W, Badrawi N et al. (2007) Oral Ibuprofen and ductus arteriosus in premature infants: a randomized pilot study. Am J Perinatol 24: 267–270

    Article  PubMed  Google Scholar 

  40. Bell EF, Acarregui MJ (2008) Restricted versus liberal water intake for preventing morbidity and mortality in preterm infants. Cochrane Database Syst Rev: CD000503

    Google Scholar 

  41. Vanhaesebrouck S, Zonnenberg I, Vandervoort P et al. (2007) Conservative treatment for patent ductus arteriosus in the preterm. Arch Dis Child Fetal Neonatal Ed 92: F244–247

    Article  PubMed  Google Scholar 

  42. Barrington K, Brion LP (2002) Dopamine versus no treatment to prevent renal dysfunction in indomethacin-treated preterm newborn infants. Cochrane Database Syst Rev: CD003213

    Google Scholar 

  43. Bouissou A, Rakza T, Klosowski S et al. (2008) Hypotension in preterm infants with significant patent ductus arteriosus: effects of dopamine. J Pediatr 153: 790–794

    Article  PubMed  Google Scholar 

  44. Brion LP, Campbell DE (2001) Furosemide for symptomatic patent ductus arteriosus in indomethacin-treated infants. Cochrane Database Syst Rev: CD001148

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Neonatologie, Universitätsklinikum Tübingen, Calwerstr. 7, 72076, Tübingen

    Axel Franz (MD)

Authors
  1. Axel Franz
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Franz, A. (2011). Missing Data for an Evidence-Based Approach to the Treatment of a Patent Ductus Arteriosus A Small Selection of What We Do not Know Yet. In: Controversies around treatment of the open duct. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-20623-8_9

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-20623-8_9

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-20622-1

  • Online ISBN: 978-3-642-20623-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation